Welcome to our dedicated page for In8Bio news (Ticker: INAB), a resource for investors and traders seeking the latest updates and insights on In8Bio stock.
Overview of IN8Bio, Inc.
IN8Bio, Inc. (Nasdaq: INAB) is a clinical-stage biotechnology company pioneering the development of gamma-delta T cell-based immunotherapies for the treatment of solid and liquid tumors. Leveraging the unique properties of gamma-delta T cells, the company focuses on creating innovative therapies that address significant unmet medical needs in oncology. Gamma-delta T cells are a specialized subset of T cells with the innate ability to differentiate between healthy and diseased tissues, making them a promising tool for targeted cancer treatment.
Core Business and Technology
IN8Bio's proprietary DeltEx platform employs allogeneic, autologous, and genetically modified approaches to develop gamma-delta T cell therapies. These therapies are designed to enhance tumor targeting, improve treatment durability, and reduce the risk of toxicities often associated with other immunotherapies. Unlike traditional CAR-T therapies, gamma-delta T cells naturally secrete lower levels of inflammatory cytokines, potentially offering a safer and more tolerable treatment option.
Key Clinical Programs
- INB-400: A Phase 2 clinical program targeting newly diagnosed glioblastoma (GBM), a highly aggressive brain tumor with limited treatment options. INB-400 combines autologous gamma-delta T cells with the standard-of-care regimen to improve progression-free and overall survival rates.
- INB-100: A Phase 1 program focused on high-risk leukemia patients undergoing hematopoietic stem cell transplantation. This therapy utilizes haplo-matched allogeneic gamma-delta T cells to reduce relapse rates and improve long-term outcomes.
- Preclinical Pipeline: The company is also exploring additional product candidates, such as INB-200 and INB-300, targeting other solid and hematologic tumors.
Market Position and Differentiation
IN8Bio operates within the competitive landscape of cell-based immunotherapies, which includes CAR-T therapies and other T cell-based approaches. However, the company differentiates itself through its focus on gamma-delta T cells, which offer unique advantages such as innate tumor recognition and reduced risk of severe toxicities like cytokine release syndrome (CRS). This positions IN8Bio as a potential leader in the next generation of immunotherapies.
Challenges and Opportunities
As a clinical-stage company, IN8Bio faces challenges such as regulatory hurdles, manufacturing scalability, and the inherent risks of clinical development. However, its innovative approach and focus on addressing unmet medical needs provide significant opportunities for growth and impact within the biopharmaceutical industry.
Conclusion
IN8Bio, Inc. represents a cutting-edge approach to cancer treatment, utilizing the unique properties of gamma-delta T cells to develop therapies with the potential to transform outcomes for patients with difficult-to-treat cancers. Through its robust pipeline and proprietary technology, the company is well-positioned to make a meaningful impact in the field of oncology.
IN8bio, a clinical-stage biopharmaceutical company, reported promising initial data from its Phase 1 trial of INB-200 in newly diagnosed glioblastoma multiforme (GBM). All three patients in Cohort 2 exceeded the median progression-free survival of seven months, with responses ongoing beyond 1.5 years. The company aims to start a Phase 2 trial of INB-400 by Q3 2023 and anticipates submitting an IND for INB-410 in 2H 2023. No serious adverse events related to treatment have been reported, indicating a favorable safety profile.
IN8bio, Inc. (Nasdaq: INAB), a biopharmaceutical leader in gamma-delta T cell therapies, announced that CEO William Ho will present at the Biotech Showcase 2023 on January 9, 2023. The company will participate in a panel discussion on innovative gene and cell therapy approaches on January 10. This event will occur at the Hilton San Francisco Union Square, coinciding with the 41st Annual J.P. Morgan Healthcare Conference from January 9-11, 2023. IN8bio is currently advancing several clinical trials for its lead products targeting glioblastoma and leukemia.
IN8bio announced positive results from the Phase 1 trial of INB-100, a gamma-delta T cell therapy for hematological malignancies. Patients in the first cohort showed durable responses, remaining progression-free for over 2.5 years. Notably, 4 patients treated at the first dose level have maintained remission, with no dose-limiting toxicities reported. Enrollment for Cohort 2 has begun, with updates anticipated in Q2 2023. The results highlight INB-100's potential to improve cure rates in high-risk acute myeloid leukemia patients undergoing haploidentical stem cell transplantation.
IN8bio has received FDA clearance for its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of INB-400, targeting newly diagnosed glioblastoma. The trial aims to assess the safety and efficacy of genetically modified DeltEx drug-resistant immunotherapy cells at various U.S. medical centers. This milestone marks IN8bio's first company-sponsored IND and sets the stage for further exploration of its DeltEx platform across solid tumor cancers. A conference call will be held on December 12 to discuss updated data from the ongoing Phase 1 trial of INB-100.
IN8bio, Inc. (Nasdaq: INAB) reported significant progress in its third quarter 2022 updates. The Phase 1 trial of INB-100 in leukemia patients showed durable morphologic complete responses with no dose-limiting toxicities. The company raised $9.8 million through an equity offering, boosting its cash position to $27.6 million. Additionally, IN8bio partnered with the Dunbar CAR T-Cell Program for INB-400 GMP production and expanded its R&D efforts, although it reported a net loss of $7.4 million for the quarter.
IN8bio, Inc. (Nasdaq: INAB) announced promising early results from its ongoing Phase 1 trial of INB-100, targeting high-risk acute myeloid leukemia (AML) patients undergoing hematopoietic stem cell transplant. Notably, all three patients in Cohort 1 are alive and progression-free, with response durations exceeding 12 to 26.5 months. The safety profile remains manageable, with no dose-limiting toxicities observed. Updated data will be presented at the upcoming ASH Annual Meeting on December 11, 2022, highlighting the potential of INB-100 to impact AML treatment paradigms.
IN8bio, a clinical-stage biopharmaceutical company, has announced that CEO William Ho will present at two investor conferences in November 2022. He will participate in the BioFuture 2022 on November 8, presenting at 9:30 a.m. ET and again at 2:30 p.m. ET. Additionally, he will present at the Stifel 2022 Healthcare Conference on November 15 at 10:20 a.m. ET. The Stifel presentation will be available live and as a replay on the company's website. IN8bio is focused on developing gamma-delta T cell therapies for solid and liquid tumors.
IN8bio, a clinical-stage biopharmaceutical company, announced that CEO William Ho will speak at the “Cell Therapy in Solid Tumors” panel during the Cantor Oncology & HemOnc Conference on September 28, 2022, at 1:45 p.m. ET. IN8bio is focused on developing innovative gamma-delta T cell therapies for solid and liquid tumors through its DeltEx platform. The company is conducting Phase 1 clinical trials for INB-200, targeting newly diagnosed glioblastoma, and INB-100 for leukemia patients undergoing stem cell transplantation, alongside its preclinical programs.
IN8bio, Inc. (Nasdaq: INAB) has partnered with the UofL Health - Brown Cancer Center for exclusive access to a GMP manufacturing facility, essential for its INB-400 Phase 2 clinical program targeting glioblastoma. This collaboration aims to enhance efficiency in T-cell therapy production, addressing a significant bottleneck for cell therapy companies. The partnership potentially allows for future expansion into commercial-scale manufacturing, supporting broader access to innovative immunotherapies for cancer patients.
IN8bio, Inc. (Nasdaq: INAB) announced that CEO William Ho will participate in a fireside chat at the H.C. Wainwright & Co. 24th Annual Global Investment Conference on September 14, 2022, at 10:30 a.m. ET. The event will be live-streamed on the IN8bio website, with a replay available for 90 days. IN8bio specializes in gamma-delta T cell therapies for cancer, focusing on innovative treatments for glioblastoma and leukemia. The company is conducting Phase 1 trials for its lead products, INB-200 and INB-100, while exploring preclinical programs for various solid tumors.
FAQ
What is the current stock price of In8Bio (INAB)?
What is the market cap of In8Bio (INAB)?
What is IN8Bio, Inc.'s primary focus?
What are gamma-delta T cells?
What are IN8Bio's key clinical programs?
How does IN8Bio differentiate itself from competitors?
What challenges does IN8Bio face?
What is the DeltEx platform?
What types of cancers does IN8Bio target?
What is INB-400?
What is the significance of INB-100?
What makes gamma-delta T cell therapies safer than CAR-T therapies?
